

OCT 06 2006  
Docket No.: 066817-0012

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Sperandio, Sabina, et al.  
Appl. No. : 10/079,929  
Filed : February 19, 2002  
Title : MODULATORS OF PARAPTOsis  
AND RELATED METHODS  
Grp./A.U. : 1647  
Examiner: : Daniel C. GAMETT

Customer No.: 41552  
Confirmation No.: 6504

CERTIFICATE OF MAILING BY EXPRESS MAIL<sup>(37)</sup>

CFR § 1.10

"Express Mail" Mailing Label Number EV 643846871 US

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Oct. 6, 2006.

  
Andrew Reese

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee.

REQUEST TO CONSIDER REFERENCE AFTER CLOSE OF PROSECUTION AND BEFORE PAYMENT OF ISSUE FEE.

The undersigned hereby requests consideration and entry of this Information Disclosure Statement and accompanying reference under 37 CFR 1.97(d).

Please charge the processing fee under 1.17(p) of \$180.00 and any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

CERTIFICATION PARAGRAPH

The undersigned certifies that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign


10/11/2006 CNGUYEN 00000020 502624 10079929  
03 FC:1806 180.00 DA

10/079,929

application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR 1.97(e)(2).

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Astrid R. Spain  
Registration No. 47,956

4370 La Jolla Village Drive, Suite 700  
San Diego, CA 92122  
Phone: 858.535.9001 ARS:dcd  
Facsimile: 858.597.1585  
**Date: October 6, 2006**

**Please recognize our Customer No. 41552  
as our correspondence address.**

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>   <b>(PTO-1449)</b>			ATTY. DOCKET NO. <b>066817-0012</b>	SERIAL NO. <b>10/079,929</b>
			<b>APPLICANT</b> <b>Sperandio, Sabina, et al.</b>	
			FILING DATE <b>February 19, 2002</b>	GROUP <b>1647</b>
<b>U.S. PATENT DOCUMENTS</b>				
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code <sub>2</sub> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US		
<b>FOREIGN PATENT DOCUMENTS</b>				
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes-Number +-Kind Codes ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
<b>OTHER ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)				
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	AA	KRAUSE, D., Transient Activation of Jun N-terminal Kinases and Protection from Apoptosis by the Insulin-like Growth Factor I Receptor Can Be Suppressed by Dicumarol, The Journal of Biological Chemistry, 6/1/2001, pp. 19244-19252, Vol. 276, No.22, American Society for Biochemistry and Molecular Biology, Inc., USA (website: <a href="http://www.jbc.org">www.jbc.org</a> )		
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.